Tag Archives: Amyloid Beta Protein

Biogen’s Aducanumab: Possibly the First Viable Drug Treatment of Alzheimer’s Disease? (BBC News)

Posted on October 24, 2019 by Dementia and Elderly Care News

Summary There were early hopes that the drug Aducanumab (from Biogen) might be able to slow down the build-up of amyloid protein in the brain, but trials were halted in March 2019 due to “disappointing” trial results. Subsequent re-analysis of … Continue reading →

Posted in BBC News, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Aducanumab: Recombinant Human Monoclonal Antibody, Aβ, Aβ Accumulation, Aβ-Plaques, Aβopathy, Amyloid Beta, Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, Amyloid-Related Imaging Abnormalities-Edema (ARIA-E), Amyloidopathy, Antibody-Based Immunotherapy Against Aβ, ARIA-E Episodes, Beta-Amyloid, Beta-Amyloid Plaques, Biogen, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Side-Effects, Drug Trials Failure Rate, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, Drugs for Treatment of Alzheimer’s Disease, Edema, β-Amyloid (Aβ) Accumulation, β-amyloid Deposition, Monoclonal Antibodies, Neurimmune, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Oedema, Phase 3 EMERGE Study, Phase 3 ENGAGE Study, Slowing of Cognitive Decline, Treatment of Alzheimer's Disease | Leave a comment

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Posted on August 3, 2019 by Dementia and Elderly Care News

Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer’s Disease onset with 94% accuracy. Due caution: “But it’s important to note … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest | Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine | Leave a comment

Further Evidence on the Association Between Poor Oral Health and the Risk of Developing Alzheimer’s Disease. New Possibilities for Treatment? (BBC News / Science Advances)

Posted on January 25, 2019 by Dementia and Elderly Care News

Summary Analysis of brain tissue, spinal fluid, and saliva from persons with Alzheimer’s Disease indicates the presence of Porphyromonas gingivalis (the bacterium associated with chronic gum disease) in the brain and central nervous system. Animal research using mice indicates that … Continue reading →

Posted in Animal Studies, BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Alzheimer's Disease and Chronic Periodontitis, Alzheimer's Disease Causation and Possible Treatments, Alzheimer’s Disease, Amyloid Beta, Amyloid Beta Protein, Arginine-Gingipain A (RgpA), Arginine-Gingipain B (RgpB), Australia, Bazian, Behind the Headlines, Beta-Amyloid Plaques, Chronic Gum Disease, Chronic Periodontitis, Common Oral Problems and Risk Factors, COR271, COR388, Cortexyme, Dementia Risk Factors, Dental Healthcare, Dental Hygiene, Evidence for Risk Factors of Dementia, Gingipain, Gingipain Inhibitors, Gum Disease, Gum Disease (Periodontitis), Gum Disease Bacteria, Harvard University School of Dental Medicine, β-Amyloid Plaques, Jagiellonian University (Poland), Lysine-Gingipain (Kgp), Mice, Modifiable Risk Factors, Neuroprotective Agents, New Zealand, Oral Health in Older Adults, Oral Healthcare, Oral Hygiene, P. gingivalis, Periodontitis, Periodontitis and Risk of Developing Alzheimer’s Disease, Poland, Porphyromonas gingivalis, Porphyromonas Gingivalis in Alzheimer’s Disease, Risk Factors, Science Advances (Journal), Small-Molecule Gingipain Inhibitors: Possibly Neuroprotective, Tau Tangles, Transgenic Mice, University of Auckland, University of California, University of Louisville School of Dentistry, University of Melbourne | Leave a comment

Preventative Treatment to Reduce Risk of Alzheimer’s Disease, Using Non-Steroidal Anti-Inflammatory Drugs? (NHS Choices / Journal of Alzheimer’s Disease)

Posted on March 31, 2018 by Dementia and Elderly Care News

Summary A recent article suggests that use of nonsteroidal anti-inflammatory drugs (NSAIDs) might help to reduce the risk of developing Alzheimer’s Disease, if prescription were to be commenced years before clinical signs were to develop. An NHS Choices Behind the … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Aβ42, Alzheimer Disease Anti-Inflammatory Prevention, Alzheimer’s Disease Biomarkers, Amyloid Beta (Aβ42), Amyloid Beta Protein, Amyloid Cascade Inflammatory Hypothesis, Amyloid-β (Aβ), Amyloidogenic and Inflammatory Pathways, Aurin Biotech, Aurin Biotech Inc. Ltd. (Vancouver), ß-amyloid, Bazian, Behind the Headlines, Biomarkers, Canada, Critical Appraisals, Dementia Risk Reduction and Prevention, Dementia Saliva Testing (Pilot Study), Diagnosis of Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels, ELISA Method to Determine Aβ42 Levels in Saliva, Fluid Biomarker Analysis, Ibuprofen, Ibuprofen and the Reduced Risk of Alzheimer’s Disease Link, Inflammation, Journal of Alzheimer's Disease, Long-Term Ibuprofen Use, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroinflammation, Non-Invasive Biomarkers, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Preclinical Biomarkers in Alzheimer's Disease, Preventative Interventions, Prevention, Saliva Tests, Salivary Amyloid-β Protein 42 Levels, Salivary Biomarkers | Leave a comment

Dementia Researchers Recognised and Rewarded (BBC News / Lundbeck Foundation)

Posted on March 7, 2018 by Dementia and Elderly Care News

Summary Four dementia researchers share the 2018 (€1 million Euro) Brain Prize (bestowed by the Lundbeck Foundation), in recognition of their joint work on the underlying neuropathological mechanisms thought to cause of Alzheimer’s Disease. Full Text Link Reference Roberts, M. … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest | Tagged Abnormal Proteins, Abnormal Proteins (Tau), Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease: Causes, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Proteins, Amyloid-β Protein, Annual €1 Million Brain Prize, Apolipoprotein E (APOE) Gene, Asymptomatic Alzheimer’s Disease, Cambridge University, Dementia Research, Dementia Research Careers, Dementia Research Funding, Genetic Research, Germany, Global Context, Global Dementia Research, Global Outlook, β-Amyloid Precursor Protein (APP), Lundbeck Foundation (Denmark), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuropathologic Disorders, Neuropathology, Pathophysiological Processes in Alzheimer’s Disease, Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Christian Haass, Professor John Hardy, Professor Michael Goedert, The Brain Prize (Lundbeck Foundation), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College London, University of Munich | Leave a comment

The Most Significant Breakthrough in the Treatment of Neurodegenerative Diseases in Fifty Years? (BBC News / UCL)

Posted on December 15, 2017 by Dementia and Elderly Care News

Summary An experimental drug for the treatment of Huntington’s Disease shows early signs of being able to lower the level of misfolded proteins (safely) in the brains of patients, thereby having the potential to slow or halt the progression of … Continue reading →

Posted in BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, UK, Universal Interest | Tagged Alzheimer's Disease, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Antisense Oligonucleotides (ASO), Biomedical Research Centres (NIHR), Canada, Clinical Trial NCT02519036, Gene Silencing to Suppress Transcription and Translation of Huntingtin, Gene-Silencing, Genetic Research, Genetics, Germany, Huntingtin Protein, Huntingtin Protein (HTT), Huntington Disease, Huntington's Disease (HD): an Autosomal-Dominant Inherited Neurodegenerative Disorder, Huntington's Disease Centre: UCL Institute of Neurology, Huntington’s Disease, Ionis Pharmaceuticals, IONIS-HTTRx: Huntingtin-Lowering Drug, α-Synuclein, α-Synuclein Aggregation, Leonard Wolfson Experimental Neurology Centre (LWENC), Leonard Wolfson Experimental Neurology Centre: University College London, Misfolded Proteins, Mutant HTT (mHTT) Protein, Mutant Huntingtin (mHTT), National Institute for Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuronal Loss, Neuroprotection, Prof. Giovanna Mallucci, Professor Sarah Tabrizi: IONIS-HTTRx Global Chief Investigator, Professor Sarah Tabrizi: UCL Institute of Neurology, Protein Misfolding, Roche, Synucleinopathy, Tau, Tau Protein, Tauopathy, University College London (UCL), University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London Hospitals NHS Foundation Trust / University College London (NIHR) Biomedical Research Centre | Leave a comment

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Posted on April 20, 2017 by Dementia and Elderly Care News

Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →

Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans | Leave a comment

Tag Archives: Amyloid Beta Protein

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Further Evidence on the Association Between Poor Oral Health and the Risk of Developing Alzheimer’s Disease. New Possibilities for Treatment? (BBC News / Science Advances)

Preventative Treatment to Reduce Risk of Alzheimer’s Disease, Using Non-Steroidal Anti-Inflammatory Drugs? (NHS Choices / Journal of Alzheimer’s Disease)

Dementia Researchers Recognised and Rewarded (BBC News / Lundbeck Foundation)

The Most Significant Breakthrough in the Treatment of Neurodegenerative Diseases in Fifty Years? (BBC News / UCL)

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites